- Home
- ATXS vs LEO Comparison
ATXS vs LEO Comparison
Compare ATXS & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- LEO
- Stock Information
- Founded
- ATXS 2008
- LEO 1987
- Country
- ATXS United States
- LEO United States
- Employees
- ATXS N/A
- LEO N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- LEO Trusts Except Educational Religious and Charitable
- Sector
- ATXS Health Care
- LEO Finance
- Exchange
- ATXS Nasdaq
- LEO Nasdaq
- Market Cap
- ATXS 401.2M
- LEO 362.5M
- IPO Year
- ATXS 2015
- LEO N/A
- Fundamental
- Price
- ATXS $7.52
- LEO $6.04
- Analyst Decision
- ATXS Buy
- LEO
- Analyst Count
- ATXS 6
- LEO 0
- Target Price
- ATXS $32.00
- LEO N/A
- AVG Volume (30 Days)
- ATXS 298.2K
- LEO 200.2K
- Earning Date
- ATXS 08-12-2025
- LEO 01-01-0001
- Dividend Yield
- ATXS N/A
- LEO 4.01%
- EPS Growth
- ATXS N/A
- LEO N/A
- EPS
- ATXS N/A
- LEO 0.04
- Revenue
- ATXS N/A
- LEO N/A
- Revenue This Year
- ATXS N/A
- LEO N/A
- Revenue Next Year
- ATXS N/A
- LEO N/A
- P/E Ratio
- ATXS N/A
- LEO $152.00
- Revenue Growth
- ATXS N/A
- LEO N/A
- 52 Week Low
- ATXS $3.56
- LEO $4.98
- 52 Week High
- ATXS $12.92
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- ATXS 64.14
- LEO 65.45
- Support Level
- ATXS $6.50
- LEO $5.83
- Resistance Level
- ATXS $6.82
- LEO $5.95
- Average True Range (ATR)
- ATXS 0.44
- LEO 0.06
- MACD
- ATXS 0.07
- LEO 0.01
- Stochastic Oscillator
- ATXS 96.62
- LEO 98.64
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.